Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe


  Drug Resistance

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 40 articles:
HTML format



Single Articles


    April 2020
  1. MELLON G, Turbett SE, Worby C, Oliver E, et al
    Acquisition of Antibiotic-Resistant Bacteria by U.S. International Travelers.
    N Engl J Med. 2020;382:1372-1374.
    PubMed    


  2. FANG FC, Schooley RT
    Antimicrobial Resistance - The Glass Is Half Full.
    N Engl J Med. 2020;382:1363-1365.
    PubMed    


  3. JERNIGAN JA, Hatfield KM, Wolford H, Nelson RE, et al
    Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017.
    N Engl J Med. 2020;382:1309-1319.
    PubMed     Abstract available


  4. ZAHEEN A, Bloom BR
    Tuberculosis in 2020 - New Approaches to a Continuing Global Health Crisis.
    N Engl J Med. 2020;382:e26.
    PubMed    


    March 2020
  5. KOZAL M, Aberg J, Pialoux G, Cahn P, et al
    Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
    N Engl J Med. 2020;382:1232-1243.
    PubMed     Abstract available


  6. SWINDELLS S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, et al
    Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
    N Engl J Med. 2020 Mar 4. doi: 10.1056/NEJMoa1904398.
    PubMed     Abstract available


  7. ORKIN C, Arasteh K, Hernandez-Mora MG, Pokrovsky V, et al
    Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
    N Engl J Med. 2020 Mar 4. doi: 10.1056/NEJMoa1909512.
    PubMed     Abstract available


    December 2019
  8. WILLIAMSON D, Ingle D, Howden B
    Extensively Drug-Resistant Shigellosis in Australia among Men Who Have Sex with Men.
    N Engl J Med. 2019;381:2477-2479.
    PubMed    


    November 2019
  9. LIETMAN TM, Doan T, Keenan JD
    Macrolide Resistance and Longer-Term Assessment of Azithromycin in MORDOR I. Reply.
    N Engl J Med. 2019;381:2184-2185.
    PubMed    


  10. PODDIGHE D
    Macrolide Resistance and Longer-Term Assessment of Azithromycin in MORDOR I.
    N Engl J Med. 2019;381:2184.
    PubMed    


  11. DEFILIPP Z, Bloom PP, Torres Soto M, Mansour MK, et al
    Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant.
    N Engl J Med. 2019;381:2043-2050.
    PubMed     Abstract available


    September 2019
  12. NUNN AJ, Phillips PPJ
    A Shorter Regimen for Rifampin-Resistant Tuberculosis. Reply.
    N Engl J Med. 2019;381:e22.
    PubMed    


  13. TORNHEIM JA, Udwadia ZF, Gupta A
    A Shorter Regimen for Rifampin-Resistant Tuberculosis.
    N Engl J Med. 2019;381:e22.
    PubMed    


  14. MCCAW ZR, Meng Z, Wei LJ
    A Shorter Regimen for Rifampin-Resistant Tuberculosis.
    N Engl J Med. 2019;381:e22.
    PubMed    


    August 2019
  15. LUBKE N, Jensen B, Huttig F, Feldt T, et al
    Failure of Dolutegravir First-Line ART with Selection of Virus Carrying R263K and G118R.
    N Engl J Med. 2019;381:887-889.
    PubMed    


  16. NIELSEN TB, Brass EP, Gilbert DN, Bartlett JG, et al
    Sustainable Discovery and Development of Antibiotics - Is a Nonprofit Approach the Future?
    N Engl J Med. 2019;381:503-505.
    PubMed    


    June 2019
  17. DOAN T, Arzika AM, Hinterwirth A, Maliki R, et al
    Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger.
    N Engl J Med. 2019;380:2271-2273.
    PubMed    


    April 2019
  18. WOJCIECHOWSKI D, Gandhi RT, Rosales IA
    Case 11-2019: A 49-Year-Old Man with HIV Infection and Chronic Kidney Disease.
    N Engl J Med. 2019;380:1464-1472.
    PubMed    


    March 2019
  19. CROWE SE
    Helicobacter pylori Infection.
    N Engl J Med. 2019;380:1158-1165.
    PubMed    


  20. NUNN AJ, Phillips PPJ, Meredith SK, Chiang CY, et al
    A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.
    N Engl J Med. 2019 Mar 13. doi: 10.1056/NEJMoa1811867.
    PubMed     Abstract available


  21. CHURCHYARD GJ
    A Short Regimen for Rifampin-Resistant Tuberculosis.
    N Engl J Med. 2019 Mar 13. doi: 10.1056/NEJMe1902904.
    PubMed    


    February 2019
  22. MCKINNELL JA, Dwyer JP, Talbot GH, Connolly LE, et al
    Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.
    N Engl J Med. 2019;380:791-793.
    PubMed    


  23. WAGENLEHNER FME, Cloutier DJ, Komirenko AS, Cebrik DS, et al
    Once-Daily Plazomicin for Complicated Urinary Tract Infections.
    N Engl J Med. 2019;380:729-740.
    PubMed     Abstract available


  24. O'RIORDAN W, Green S, Overcash JS, Puljiz I, et al
    Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.
    N Engl J Med. 2019;380:528-538.
    PubMed     Abstract available


    November 2018
  25. BLANK S, Daskalakis DC
    Neisseria gonorrhoeae - Rising Infection Rates, Dwindling Treatment Options.
    N Engl J Med. 2018;379:1795-1797.
    PubMed    


    October 2018
  26. ANDREWS JR, Qamar FN, Charles RC, Ryan ET, et al
    Extensively Drug-Resistant Typhoid - Are Conjugate Vaccines Arriving Just in Time?
    N Engl J Med. 2018;379:1493-1495.
    PubMed    


    September 2018

  27. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.
    N Engl J Med. 2018 Sep 26. doi: 10.1056/NEJMoa1800474.
    PubMed     Abstract available


    August 2018
  28. COLANGELI R, Jedrey H, Kim S, Connell R, et al
    Bacterial Factors That Predict Relapse after Tuberculosis Therapy.
    N Engl J Med. 2018;379:823-833.
    PubMed     Abstract available


  29. EMU B, Fessel J, Schrader S, Kumar P, et al
    Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
    N Engl J Med. 2018;379:645-654.
    PubMed     Abstract available


  30. SHEIKH V, Murray JS, Sherwat A
    Ibalizumab in Multidrug-Resistant HIV - Accepting Uncertainty.
    N Engl J Med. 2018;379:605-607.
    PubMed    


    April 2018
  31. KEENAN JD, Bailey RL, West SK, Arzika AM, et al
    Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa.
    N Engl J Med. 2018;378:1583-1592.
    PubMed     Abstract available


    March 2018
  32. GOTTLIEB GS, Raugi DN, Smith RA
    HIV Drug Resistance.
    N Engl J Med. 2018;378:874-5.
    PubMed    


  33. BERTAGNOLIO S, Jordan MR, Doherty M
    HIV Drug Resistance.
    N Engl J Med. 2018;378:874.
    PubMed    


  34. INZAULE SC, Rinke de Wit TF, Hamers RL
    HIV Drug Resistance.
    N Engl J Med. 2018;378:873-4.
    PubMed    



  35. HIV Drug Resistance.
    N Engl J Med. 2018;378:873-875.
    PubMed    


    October 2017
  36. BEYRER C, Pozniak A
    HIV Drug Resistance - An Emerging Threat to Epidemic Control.
    N Engl J Med. 2017;377:1605-1607.
    PubMed    


    September 2017
  37. MANNING BD
    Game of TOR - The Target of Rapamycin Rules Four Kingdoms.
    N Engl J Med. 2017;377:1297-9.
    PubMed    


  38. XIE YL, Chakravorty S, Armstrong DT, Hall SL, et al
    Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis.
    N Engl J Med. 2017;377:1043-1054.
    PubMed     Abstract available


    June 2017
  39. RUBIN EJ
    Reviving a Drug for Tuberculosis?
    N Engl J Med. 2017;376:2292-2294.
    PubMed    


  40. BOURLIERE M, Gordon SC, Flamm SL, Cooper CL, et al
    Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
    N Engl J Med. 2017;376:2134-2146.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Drug Resistance is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: